Clinical Trial

Belumosudil for the Pre-emptive Treatment of Patients With Chronic Graft Versus Host Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial compares the effect of belumosudil to a placebo in treating patients with chronic graft versus host disease. Chronic graft versus host disease remains a major complication of stem cell transplantation and can involve multiple organ systems. Belumosudil is a ROCK2 selective inhibitor that works to reduce the immune system response causing the chronic graft versus host disease. Giving belumosudil may better treat patients with chronic graft versus host disease and prevent the need for starting additional immune suppressive medications.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2023-08-10; most recent amendment 2026-06-03.
Status change: Not Yet Recruiting → Recruiting 2023-11-01
Trial Details
NCT Number NCT05996627
Lead Sponsor Fred Hutchinson Cancer Center
Collaborators: Sanofi
Conditions Chronic Graft Versus Host Disease
Enrollment 82 participants
Start Date 2023-12-06
Primary Completion 2028-04-30 (estimated)
Study Completion 2028-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-04